Marc A Kowalkowski1, Jennifer R Kramer2, Peter R Richardson2, Insia Suteria2, Elizabeth Y Chiao2. 1. Carolinas Healthcare System, Levine Cancer Institute College of Health and Human Services, University of North Carolina at Charlotte. 2. Department of Medicine, Baylor College of Medicine Center of Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Abstract
BACKGROUND: Kaposi sarcoma (KS) incidence has decreased since combination antiretroviral therapy (cART). However, effects of cART type and duration on KS remain difficult to interpret secondary to KS-associated immune reconstitution inflammatory syndrome (IRIS). METHODS: We performed a retrospective study of Veterans Affairs Human Immunodeficiency Virus Clinical Case Registry data from 1985 to 2010. We analyzed the relationship between cART regimens and KS using multivariable Poisson regression, stratified or adjusted for timing around cART initiation. KS was identified by ≥ 1 inpatient or ≥ 2 outpatient International Classification of Diseases, Ninth Revision codes (176.0-9). Percent of cART on specific regimen and total duration on specific regimen were examined. RESULTS: There were 341 KS cases among 25 529 HIV-infected male veterans (incidence rate = 2.02/1000 person-years). Stratified by years after starting cART, every additional 10% time on boosted protease inhibitors (BPIs) was associated with reduced KS incidence in the third year of cART (incidence rate ratio [IRR] = 0.79; 95% confidence interval [CI], .69-.90). Months on BPIs was associated with lower KS incidence (P = .02). KS incidence was lower at 12-23 (IRR = 0.47; 95% CI, .23-.95) and ≥ 36 (IRR = 0.14; 95% CI, .02-1.00) months on BPIs compared with <6 months. Longer duration on other regimens was not associated with decreased KS incidence. CONCLUSIONS: Lower KS incidence was observed with longer BPI use, after accounting for potential IRIS and other factors. Future research should evaluate newer cART regimens and long-term benefits of PI-based cART on KS in other cohorts and prospective studies.
BACKGROUND:Kaposi sarcoma (KS) incidence has decreased since combination antiretroviral therapy (cART). However, effects of cART type and duration on KS remain difficult to interpret secondary to KS-associated immune reconstitution inflammatory syndrome (IRIS). METHODS: We performed a retrospective study of Veterans Affairs Human Immunodeficiency Virus Clinical Case Registry data from 1985 to 2010. We analyzed the relationship between cART regimens and KS using multivariable Poisson regression, stratified or adjusted for timing around cART initiation. KS was identified by ≥ 1 inpatient or ≥ 2 outpatient International Classification of Diseases, Ninth Revision codes (176.0-9). Percent of cART on specific regimen and total duration on specific regimen were examined. RESULTS: There were 341 KS cases among 25 529 HIV-infected male veterans (incidence rate = 2.02/1000 person-years). Stratified by years after starting cART, every additional 10% time on boosted protease inhibitors (BPIs) was associated with reduced KS incidence in the third year of cART (incidence rate ratio [IRR] = 0.79; 95% confidence interval [CI], .69-.90). Months on BPIs was associated with lower KS incidence (P = .02). KS incidence was lower at 12-23 (IRR = 0.47; 95% CI, .23-.95) and ≥ 36 (IRR = 0.14; 95% CI, .02-1.00) months on BPIs compared with <6 months. Longer duration on other regimens was not associated with decreased KS incidence. CONCLUSIONS: Lower KS incidence was observed with longer BPI use, after accounting for potential IRIS and other factors. Future research should evaluate newer cART regimens and long-term benefits of PI-based cART on KS in other cohorts and prospective studies.
Authors: Simone Gaedicke; Elke Firat-Geier; Oana Constantiniu; Maria Lucchiari-Hartz; Marina Freudenberg; Chris Galanos; Gabriele Niedermann Journal: Cancer Res Date: 2002-12-01 Impact factor: 12.701
Authors: Justin Stebbing; Simon Portsmouth; Mark Nelson; Sundhiya Mandalia; Hala Kandil; Nic Alexander; Liz Davies; Cathryn Brock; Mark Bower; Brian Gazzard Journal: Int J Cancer Date: 2004-02-10 Impact factor: 7.396
Authors: Henry K Tam; Zuo-Feng Zhang; Lisa P Jacobson; Joseph B Margolick; Joan S Chmiel; Charles Rinaldo; Roger Detels Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396
Authors: Cecilia Sgadari; Giovanni Barillari; Elena Toschi; Davide Carlei; Ilaria Bacigalupo; Sara Baccarini; Clelia Palladino; Patrizia Leone; Roberto Bugarini; Laura Malavasi; Aurelio Cafaro; Mario Falchi; Donatella Valdembri; Giovanni Rezza; Federico Bussolino; Paolo Monini; Barbara Ensoli Journal: Nat Med Date: 2002-03 Impact factor: 53.440
Authors: Simon Portsmouth; Justin Stebbing; Jas Gill; Sundhiya Mandalia; Mark Bower; Mark Nelson; Mark Bower; Brian Gazzard Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Elaine Chang; Srikar R Mapakshi; Pamela Mbang; Nader Kim El-Mallawany; Jennifer R Kramer; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.771
Authors: I Poizot-Martin; V Obry-Roguet; C Duvivier; C Lions; T Huleux; C Jacomet; T Ferry; A Cheret; C Allavena; F Bani-Sadr; R Palich; A Cabié; A Fresard; P Pugliese; P Delobel; I Lamaury; L Hustache-Mathieu; S Brégigeon; A Makinson; D Rey Journal: J Eur Acad Dermatol Venereol Date: 2020-04-30 Impact factor: 6.166